Satellite Educational Symposia will take place at the San Antonio Marriott Rivercenter. These are not official programs of the San Antonio Breast Cancer Symposium®.
Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life
Salons ABF
This activity is supported by an educational grant from Pfizer, Inc.
Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium
Salons CDE
This symposium is sponsored by Physicians’ Education Resource, LLC (PER) and is supported by grants from AstraZeneca; BioNTech; Genentech, Inc; and Stemline Therapeutics, Inc. This is not an official program of SABCS.
Dialing Up Precision in HR+, HER2- MBC With New Endocrine Agents, Targeted Therapies, and Combinations
Salons ABF
This activity is supported by independent educational grants from AstraZeneca, Genentech, a member of the Roche Group, Lilly, and Stemline Therapeutics, a Menarini Company Group.
Cases from the Community: Investigators Discuss the Role of Antibody-Drug Conjugates in the Management of Triple-Negative and HR-Positive Metastatic Breast Cancer
Salons HIJKL
This symposium is sponsored by Research To Practice and supported by grants from Gilead Sciences Inc and Helsinn Therapeutics (US) Inc.
Medical Crossfire® – Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer: Expert Perspectives on Applying Modern Treatment Paradigms
Salons CDE
This activity is supported by educational grants from AstraZeneca, Merck Sharp & Dohme Corp.
Extending Efficacy: New Approaches for Endocrine- Resistant HR+/HER2- Advanced Breast Cancer
Salons GM
This activity is supported by Celcuity, Inc.
Medical Crossfire® The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer
Grand Ballroom Salons CDE
This Symposium is sponsored by Physicians’ Education Resource (PER) and is supported by grants from AstraZeneca; BioNTech; Daiichi Sankyo, Inc; and Merck Sharp & Dohme Corp. This is not an official program of SABCS.
Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic HR+, HER2- Breast Cancer
Salons ABF
This activity is supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.
Cases from the Community: Investigators Discuss the Optimal Management of HER2-Positive Breast Cancer
Salons HIJKL
This symposium is sponsored by Research To Practice and supported by grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc.
Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?
Salons CDE
This activity is supported by educational grants from Arvinas and Pfizer, Inc.
Forging New Paths With Earlier Use of ADCs in Breast Cancer
Salons ABF
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Cases from the Community: Investigators Discuss the Optimal Role of Endocrine-Based and Other Strategies in the Management of HR-Positive Breast Cancer
Salons HIJKL
This symposium is sponsored by Research To Practice and supported by grants from Agendia Inc, Celcuity, Exact Sciences Corporation, Genentech, a member of the Roche Group, Hologic Inc, Lilly, and Stemline Therapeutics Inc. This is not an official program of the San Antonio Breast Cancer Symposium®️ (SABCS®️).